DAXOR CORP (DXR) - 10-K Summary for Fiscal Year Ended December 31, 2008
Business Context and Reporting Period
Company: Daxor Corporation
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2008
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and the Volumex radiopharmaceutical kit. It also operates Scientific Medical Systems, a subsidiary providing cryobanking services for blood and semen (Idant). The company relies heavily on investment income to offset operating losses.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Operating Revenues | $1,761,055 | $1,869,779 |
| Loss from Operations | ($5,207,152) | ($5,430,870) |
| Net Income | $15,123,269 | $10,647,216 |
| Earnings Per Share (Diluted) | $3.46 | $2.33 |
| Total Assets | $76,824,181 | $102,560,500 |
| Investment Portfolio Market Value | $68,339,143 | $74,919,193 |
| Short-Term Debt | $32,973,248 | $47,214,047 |
| Cash and Cash Equivalents | $2,545,040 | $2,029,834 |
Note: Net income is driven primarily by investment gains ($17.2M) and mark-to-market adjustments on short positions ($5.4M), not core operations.
Material Changes vs. Prior Period
- Operating Revenue Decline: Total operating revenues decreased 6% to $1.76M. Equipment sales dropped from $390,500 (6 units) in 2007 to $260,000 (4 units) in 2008. Kit sales increased 4% due to higher utilization of existing instruments.
- Investment Performance: Realized gains on the sale of investments increased significantly to $17.25M (from $14.85M in 2007), largely due to a merger-related sale. Mark-to-market gains on short positions surged to $5.36M (from $357k in 2007).
- Dividends: The company paid a total of $1.50 per share in dividends ($6.45M total) in 2008, the first dividend payment since 1997.
- Balance Sheet: Total assets decreased by approximately $25.7M, primarily due to a reduction in the investment portfolio's market value and a decrease in securities borrowed (short positions) from $20.4M to $108k.
Guidance, Outlook, Risks, and Contingencies
- Reimbursement Risk: A significant CMS policy change effective January 1, 2008, eliminated separate Medicare reimbursement for diagnostic radiopharmaceuticals (Volumex) in outpatient settings. Hospitals must now absorb the cost, though procedure codes were adjusted. The impact on private insurers is unclear.
- Customer Concentration: Three hospitals accounted for 49.5% of Blood Volume Kit sales. The loss of any single customer could adversely affect the business.
- Key Person Risk: The company is significantly dependent on Dr. Joseph Feldschuh (CEO/Chief Scientist) for scientific expertise and investment management.
- Supply Chain Risk: Volumex syringes are filled by a single FDA-approved manufacturer. Disruption of this supply would be material.
- Investment Strategy: The company maintains a portfolio primarily of utility stocks and engages in short selling and option strategies. Management notes that without this investment income, the company would have faced persistent losses and potential bankruptcy.
- Legal Proceedings: One pending legal action exists, which management believes has substantial defenses.
Investor Verification Checklist
- Investment Income Sustainability: Verify the volatility of the investment portfolio and the reliance on short-term capital gains to fund operations and dividends.
- Reimbursement Impact: Assess the actual financial impact of the CMS policy change on hospital adoption of the BVA-100 and Volumex kits.
- Customer Concentration: Confirm the status of the three major hospital customers representing nearly 50% of kit revenue.
- Operating Loss Trend: Review the trajectory of the core operating loss (approx. $5.2M) and the company's ability to achieve profitability without investment income.
- Dividend Policy: Evaluate the sustainability of the new dividend policy given the company's continued operating losses and reliance on investment returns.